ArticleThe oncologist2024

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.

Kathryn E Beckermann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.